tislelizumab,sorafenib
beigene,bayer,novartis
['rationale-301', 'hcc', 'medsir']
rationale-301 (final results): primary endpoint of os non-inferiority was met. also tis achieved higher orr (14.3% vs 5.4%) and more durable responses (mdor: 36.1 mo vs 11.0 mo) compared to sor as 1l option for pts with unresectable hcc. presented by masatoshi kudo at #esmo22 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM